

AUTHOR INDEX

- Alpern, R.J., 393
Anderson, S., 441
Andoh, T.F., 34

Baum, M., 423
Becker, B.N., 176
Bennett, P.H., 124
Bennett, W.M., 1, 34
Berns, J.S., 15, 54
Bomzon, A., 549
Border, W.A., 455
Breyer, J.A., 114
Burdmann, E.A., 34

Cheung, A.K., 196
Coffman, T.M., 404
Cohen, R.M., 15

Depner, T.A., 285

Epstein, M., 503, 563, 576

First, M.R., 373
Fogo, A., 396
Ford, P.A., 54
Friedlander, M.A., 331

Gentilini, P., 530
Gibney, R., 218
Glasscock, R.J., 387

Goldfarb, S., 15
Gomez, R.A., 492
Goral, S., 364

Hakim, R.M., 149, 246, 253
Helderman, J.H., 364
Henrich, W.L., 257
Henriksen, J.H., 505
Hilgers, K.F., 492
Holt, S., 549
Hostetter, T.H., 93, 431
Hricik, D.E., 331
Hull, A.R., 160
Humes, H.D., 381

Ibrahim, H.N., 431
Ichikawa, I., 396
Imig, J.D., 412
Ismail, N., 149, 253, 270

Kaplan, A.A., 576
Kapoian, T., 239
Kennefick, T.M., 441

Laffi, G., 530
La Villa, G., 530
Levy, M., 520
Lewis, E.J., 77
Leypoldt, J.K., 196

McCurser, F.X., 226
Marra, F., 530
Matsusaka, T., 396
Meyer, T.W., 124
Molitch, M.E., 101
Moller, S., 505
Moore, K., 549
Morris, P.J., 188
Murthy, B.V.R., 346
Myers, B.D., 124

Navar, L.G., 412
Nelson, R.G., 124
Noble, N.A., 455
Norwood, V.F., 492

O'Bryan, G.T., 93

Paganini, E.P., 306
Parker, T.F., III, 149, 253
Pereira, J.G., 346
Pinzani, M., 530

Quan, A., 423

Rodby, R.A., 132
Rosenberg, M.E., 431
Rudnick, M.R., 15
Rutherford, W.E., 218

Schoenfeld, P.Y., 321
Schreiner, G.E., 152
Sharma, K., 80
Sherman, R.A., 239
Steinman, T.I., 298
Stone, W.J., 176
Swan, S.K., 27

Teehan, B.P., 226
Textor, S.C., 67
Thornton, T.A., 246

Van Stone, J.C., 214
Venkatesan, J., 257

Wang, C.T., 412
Weber, K.T., 467
Wedeen, R.P., 46
Wolf, G., 448
Woods, J.D., 381

Yagi, N., 306
Young, E.W., 170

Zager, R.A., 3
Ziyadeh, F.N., 80, 448
Zou, L., 412

SUBJECT INDEX

- AA (arachidonic acid) derivatives, *see* Leukotrienes; Prostaglandins; Thromboxane(s); Thromboxane A₂
Absolute fibrosis, described, 468
ACE, *see* Angiotensin-converting enzyme
Acidosis, *see* Metabolic acidosis in ESRD
Active proteins, HD membrane transport of oncotonically, 200
Acute bile duct ligation (BDL) models of biliary obstruction effects on renal function, 552
Acute lead nephropathy, 46
Acute renal failure (ARF)
HD membrane effects on outcome of, 207
see also Acute renal failure, CRRT of; Acute renal failure, nephrotoxic
Acute renal failure (ARF), CRRT of, 306-320
advantages and disadvantages of, 313-315
applications of, 311-312
components of, 307-309
and CRRT for conditions other than ARF, 312-313
CRRT defined, 307
dialysis dose with, 309-310
future role of, 316-317
outcome of, 315-316
Acute renal failure (ARF), nephrotoxic, 3-14
cellular energetics alterations and, 4-5
contrast-media, *see* Contrast media-associated nephropathy
determinants of nephrotoxin uptake in, 3-4
homeostasis disturbances and, *see* Homeostasis disturbances in nephrotoxic ARF

oxidative stress and, 5-7
pathways potentially contributing to, 10-12
Adenosine, role of, in HRS, 570-571
Adequacy of dialysis
of CAPD dose for ESRD, 228-232
see also Kt/V
Adsorption, protein, by HD membranes, 200-202
Advanced glycation end-products (AGEs)
and hyperglycemia in diabetic nephropathy development, 83-85
in pathogenesis of comorbid conditions with ESRD secondary to DM, 340-342
Advantages and disadvantages
of CRRT in ARF, 313-315
of rHuEPO for predialysis anemia in CRF, 273-274
Adverse effects of metabolic acidosis in predialysis CRF patients, 278
AGE(s), *see* Advanced glycation end-products
Age
donor, renal graft survival according to, 374
as risk factor for NIDDM nephropathy, 135
Aging, *see entries beginning with term:* Older
Albumin excretion
in IDDM nephropathy, 101, 102, 104-109
in NIDDM nephropathy, renal morphology according to, 129
see also Proteinuria

- Aldose reductase inhibitors in IDDM nephropathy management, 118-119
- Aldosterone, role of, in progression of renal disease, 435-437; *see also* Renin-angiotensin-aldosterone system, role of, in renal disease progression
- Alkali therapy of metabolic acidosis in predialysis CRF patients, 280
- Allergic reactions, *see* Anaphylactoid reactions to HD membranes
- Alpha (α) blockers, 262, 263
- Amadori glycation end-products, and hyperglycemia in diabetic nephropathy development, 85
- Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis for ESRD
- Aminoglycoside nephrotoxicity, 27-33
- described, 28-29
- effects of once-daily dosing on, 29-30
- experimental nephroprotection against, 29
- pharmacology and renal handling of aminoglycosides and, 27-28
- Amputation, peripheral vascular disease and, in patients with ESRD secondary to DM, 339
- β_2 (beta₂)m Amyloidosis due to HD membranes, 206
- Anaphylactoid reactions to HD membranes, 205-206
- to reused dialyzers, 324-325
- Anemia in ESRD
- myocardial dysfunction and, 257-260, 264
- see also* Anemia in predialysis CRF patients; Recombinant human erythropoietin for anemia of ESRD
- Anemia in predialysis CRF patients, 270-274
- correction of, *see* Recombinant human erythropoietin for predialysis anemia in CRF
- historical perspective on, 270
- mechanisms and characteristics of, 271
- Angiotensin II (ANG II)
- introduction to, 393-395
- see also* Angiotensin II receptors; Angiotensinogen receptor gene targeting; Diabetic nephropathy, ANG II in; RAS and; Fibrosis, as pathway to organ failure; Intrarenal angiotensin II; Proximal tubule transport, ANG II regulation of; Renal fibrosis, ANG II in; Renin-angiotensin-aldosterone system, role of, in renal disease progression; Renin-angiotensin system; Tubular hypertrophy, ANG II-induced
- Angiotensin II (ANG II) receptors
- ACE and, in repair of fibrotic tissue, 474-478
- functions and role of, 404-405
- phenotypes of, 397-401
- in proximal tubule transport, ANG II and, 425-426
- see also* AT₁ angiotensin II receptor; AT_{1A} angiotensin II receptor; AT_{2A} angiotensin II receptor
- Angiotensin-converting enzyme (ACE)
- ANG II receptors and, in repair of fibrotic tissue, 474-478
- see also* Angiotensin-converting enzyme gene; Angiotensin-converting enzyme inhibitors
- Angiotensin-converting enzyme (ACE) gene, insertion/deletion polymorphism of, as risk factor for NIDDM nephropathy, 137
- Angiotensin-converting enzyme (ACE) inhibitors, 80
- antagonism between AT₁ ANG II receptor and, in repair of fibrotic tissue, 478-479
- for dialyzed ESRD patients, 262, 263
- in IDDM nephropathy with, 115-118
- in NIDDM nephropathy, 142-143
- RAS blockade with, during renal development, 495-496
- see also* Angiotensin-converting enzyme inhibitors, renal failure related to
- Angiotensin-converting enzyme (ACE) inhibitors, renal failure related to, 67-76
- hyperkalemia and, 73-74
- incidence of, 68-70
- management and prevention of, 74-75
- pathophysiology and clinical presentation of, 70-71
- reversibility of, 71-72
- Angiotensinogen receptor gene targeting, 396-403
- ANG II receptor phenotypes and, 397-401
- angiotensinogen phenotypes and, 396-397
- and local versus systemic action of ANG II, 401-403
- ANPs, *see* Atrial natriuretic peptides
- Antibodies, *see* Monoclonal antibody(ies)
- Antihypertensive agents, *see* Hypertension and specific anti-hypertensive agents; *for example:* Angiotensin-converting enzyme inhibitors
- Anti-inflammatory drugs, non-steroidal, *see* Prostaglandins in cirrhosis
- Anti-lipidemic agents, *see* Lipid management
- Antilymphocyte agents, 191, 192
- Apoptosis in nephrotoxic ARF, 11-12
- Arachidonic acid derivatives, *see* Leukotrienes; Prostaglandins; Thromboxane(s); Thromboxane A₂
- ARF, *see* Acute renal failure
- Arsenic-induced nephropathy, 51
- Arterial blood volume in cirrhosis, 508-509
- Arteriovenous fistula (AVF) in ESRD, 240-243
- decline in use of, 243
- described, 240-241
- materials used for, 241-242
- with myocardial dysfunction, 264
- Assessment of ESRD patient's goals in rehabilitation program, 247-248, 250-251
- AT₁ (type 1) angiotensin II (ANG II) receptor, antagonism between ACE inhibitors and, in repair of fibrotic tissue, 478-479
- AT_{1A} (type 1A) angiotensin II (ANG II) receptor
- AT₂ receptor compared with, 404-405
- proximal tubule transport by ANG II and, 425-426
- see also* Physiology of AT_{1A} angiotensin II receptor, gene targeting approach to
- AT₂ (type 2) angiotensin II (ANG II) receptor
- AT_{1A} receptor compared with, 404-405
- and proximal tubule transport regulation by ANG II, 425-426
- Atrial natriuretic peptides (ANPs)
- levels of, in HRS, 570
- see also* Atrial natriuretic peptides in cirrhosis
- Atrial natriuretic peptides (ANPs) in cirrhosis
- abnormalities of, 510
- see also* Atrial natriuretic peptides in cirrhosis, renal effects of
- Atrial natriuretic peptides (ANPs) in cirrhosis, renal effects of, 520-529
- circadian patterns of, 527

- in experimental cirrhosis, 522-525
in human cirrhosis, 525
perspectives on, 527-528
pharmacological effects, 521
plasma levels of, 521-522
resistance to, 527
water immersion in study of, 525-527
- Autoimmune disease, chronic cyclosporine nephrotoxicity in, 37-38
- Automated systems of dialyzer reuse, manual versus, 323
- Autonomic dysfunction with myocardial dysfunction in ESRD, 265
- Autonomic neuropathy in ESRD secondary to DM, management of, 339
- AVF, *see* Arteriovenous fistula in ESRD
- Axial heterogeneity of proximal tubule transport regulation by ANG II, 426
- BDL (bile duct ligation) models, acute and chronic, of biliary obstruction effects on renal function, 552
- Benefits, *see* Advantages and disadvantages
- Beryllium-induced nephropathy, 51
- Beta (β) blockers for hypertensive dialyzed ESRD patients, 262, 263
- Beta (β_2) microglobulin (β_2m) amyloidosis due to HD membranes, 206
- BF, *see* Blood flow
- Bile acids, 549-562
- biliary obstruction and, *see* Biliary obstruction, effects of biosynthesis and chemistry of, 549-550
- oxidative stress and, *see* Oxidative stress, bile acids and plasma and urinary, in liver disease, 550-551
- renal function and, 551-554
- Bile duct ligation (BDL) models, acute and chronic, of biliary obstruction effects on renal function, 552
- Biliary obstruction, effects of, 552-554
- oxidative stress and, 557-558; *see also* Oxidative stress, bile acids and
- on renal function, 552-553
- on renal membrane function, 553-554
- on systemic hemodynamics, 554
- see also* Bile acids
- Bioartificial hemofilter, 383-384
- Bioartificial kidney, 381-386
- bioartificial hemofilter and, 383-384
- bioartificial renal tubule and, 384-385
- implantable, 385-386
- Bioartificial renal tubule, 384-385
- Biochemical events, *see* Hyperglycemia, diabetic nephropathy and, biochemical events and cytokines in link between
- Biochemistry
- of bile acids, 549-550
- of PGs, 530-534
- Biocompatibility of HD membranes, 202-205
- cytokine hypothesis of, 204-205
- defined, 202-203
- enhancing, 209
- neutrophil and complement activation as indices of, 203-204
- Blood flow (BF)
- in cirrhosis, 506
- renal, PG effects on, 533
- Blood pressure
- effects of AT_{1A} ANG II receptor deficiency on regulation of, 406-408
- see also* Hypertension
- Blood purification for hepatic failure, *see* Extracorporeal blood purification for hepatic failure
- Blood transfusions, number of received, as risk factor for HCV infection in dialyzed ESRD patients, 347
- Blood volume, arterial and central, in cirrhosis, 508-509
- Bone disease, *see* Renal osteodystrophy
- Bone effects of metabolic acidosis in predialysis CRF patients, 279-280
- Bone marrow transplantation, nephrotoxicity of, 60-62
- Brequinar sodium, 368
- Ca (calcium), disturbed homeostasis of cell, in nephrotoxic ARF, 7-8
- Ca (calcium) channel blockers
- in dialyzed ESRD patients, 262, 263
- in NIDDM nephropathy, 143-144
- Cadaver kidneys, strategies to enhance procurement of, 376-379
- Cadmium nephropathy, 48-49
- Calcification and fibrosis, myocardial, and myocardial dysfunction in ESRD, 265
- Calcitonin-gene related peptide (CGRP) in cirrhosis, 510
- Calcium, *see* Ca; Ca channel blockers
- Cancer therapy, renal toxicities of, 54-66
- and of bone marrow transplantation, 60-62
- of carboplatin, 55-56
- of cisplatin, 54-55
- of cyclophosphamide, 56
- of gallium nitrate, 60
- of ifosfamide, 56-57
- of IL-2, 59-60
- of methotrexate, 58-59
- of mitomycin C and plicamycin, 58
- of nitrosoureas, 57-58
- CAPD, *see* Continuous ambulatory peritoneal dialysis for ESRD
- Capitation, *see* Monthly Capitation payment in Medicare Program
- Carboplatin, nephrotoxicity of, 55-56
- Carcinogenicity of disinfectants used for dialyzers, 325
- Cardiovascular system in ESRD
- effects of metabolic acidosis on, in predialysis patients, 280
- see also* Myocardial dysfunction in ESRD
- Catecholamines in cirrhosis, 510-511
- Catheters, permanent vascular access with, 242-243
- Causes of ESRD, 170-175
- currently attributed, 170-171
- potentially unattributed, 171-172
- and reasons for increased incidence of ESRD, 172-174
- see also specific causes of ESRD; for example:* Diabetes mellitus, ESRD secondary to
- CCPD (continuous cycling peritoneal dialysis) for ESRD, 176, 179, 183

- Cell Ca (calcium), disturbed homeostasis of, in nephrotoxic ARF, 7-8
- Cellular energetics, nephrotoxic ARF and alterations in, 4-5
- Cellulosic hemodialysis (HD) membranes, 196-198
 regenerated, 196-197
- Central blood volume in cirrhosis, 508-509
- Central circulation time in cirrhosis, 505-508
- Central sympatholytic agents for hypertensive dialyzed ESRD patients, 262-263
- CGRP (calcitonin-gene related peptide) in cirrhosis, 510
- Chemical disinfection of dialyzers, 322-323
- Chemical infusion, residual, with reused dialyzers, 325-326
- Chemical toxicity of reused dialyzers, 324-325
- Chemistry, *see* Biochemistry
- Cholestasis
 oxidative stress and, 556
 see also Bile acids
- Chromium-induced nephropathy, 51
- Chronic bile duct ligation (BDL) models of biliary obstruction effects on renal function, 552
- Chronic cyclosporine nephrotoxicity, 35-40
 in autoimmune disease, 37-38
 pathophysiology of, 38-40
 in transplantation, 35-37
- Chronic lead nephropathy, 46-47
- Chronic renal failure, *see* End-stage renal disease
- Chronic renal replacement therapy *see* Continuous renal replacement therapy
- Chronic volume overload, and myocardial dysfunction in ESRD, 264
- Cigarette smoking, as risk factor for NIDDM nephropathy, 137
- Circadian patterns of ANPs, renal effects of, in cirrhosis, 527
- Circulating angiotensin II (ANG II), elevated, and repair of fibrotic tissue, 480-481
- Circulation time, central, in cirrhosis, 506-508
- Circulatory abnormalities in cirrhosis, 505-519
 in blood volume, 508-509
 in hemodynamics, *see* Systemic hemodynamics in cirrhosis
 in vasoactive substances, *see* Vasoactive substances, abnormalities of, in cirrhosis
- Cirrhosis, *see* Atrial natriuretic peptides in cirrhosis; Circulatory abnormalities in cirrhosis; Prostaglandins in cirrhosis
- Cisplatin, nephrotoxicity of, 54-55
- Clinical features and presentation
 of ACE-related renal failure, 70-71
 of CM-AN, 16-17
 of HRS, 563-564
 of TB in dialyzed ESRD patients, 355-356
- Clinical sequelae, *see* Complication(s)
- CM-AN, *see* Contrast media-associated nephropathy
- Collagen at site of tissue repair in fibrosis, 473-474
- Collapse fibrosis, described, 468
- Combined filter/sorbent systems, blood purification with, in hepatic failure, 581
- Complication(s)
 secondary to DM, role of AGEs in pathogenesis of, 340-342
 see also Myocardial dysfunction in ESRD; Therapy and management of comorbid conditions in ESRD secondary to DM
- Compartmentalization of intrarenal ANG II, 416-419
- Complement, activation of, as index of HD membrane biocompatibility, 203-204
- Complication(s)
 of ESRD avoidance of, 389
 related to choice of HD membrane, 205-208
 see also Comorbid conditions with ESRD; Complication(s) of dialyzer reuse for ESRD
- Complication(s) of dialyzer reuse for ESRD, 323-328
 chemical toxicity as, 324-325
 concentration control problems as, 326-328
 residual chemical infusion as, 325-326
- Composition, *see* Materials and composition
- Confrontation era, legislative and regulatory process of Medicare ESRD Program in, 163-164
- Confusion era, legislative and regulatory process of Medicare ESRD Program in, 161-162
- Consent for organ donation, presumed, 378
- Continued assessment of ESRD patient's goals in rehabilitation program, 250-251
- Continuous ambulatory peritoneal dialysis (CAPD) for ESRD, 226-237
 dose of, *see* Dose, CAPD, for ESRD
 HD compared with, 234-235; *see also* Hemodialysis for ESRD
 in pre-Medicare era, 227
 as RRT option, 176, 177, 179, 181, 183, 185
- Continuous cycling peritoneal dialysis (CCPD) for ESRD, 176, 179, 183
- Continuous quality improvement (CQI) in ESRD care, 221-223
 evidence-based medicine and, 222-223
 government and, 221-222
 information systems and, 223
 RPA and, 222
- Continuous renal replacement therapy (CRRT)
 for blood purification in hepatic failure, 578-580
 see also Acute renal failure, CRRT of; Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis; End-stage renal disease, CRRT of
- Contraindications to renal transplantation referral, 180
- Contrast media-associated nephropathy (CM-AN), 15-26
 clinical features of, 16-17
 incidence of, 17
 low versus high osmolality contrast media and, 19-21
 pathogenesis of, 15-16
 prophylaxis of, 21-22
 risk factors for, 17-18
- Coronary artery disease in ESRD secondary to DM, management of, 338-339
- Cost-effectiveness of rehabilitation program for ESRD patient, 251
- Cost reduction
 in Medicare Program, regulations for, 164-166
 see also Future dialysis facility
- CQI, *see* Continuous quality improvement in ESRD care
- Creatinine clearance, as measure of CAPD dose adequacy, 229-232
- CRF (chronic renal failure), *see* End-stage renal disease
- CRRT, *see* Continuous renal replacement therapy
- Currently attributed causes of ESRD, 170-171

- Cycling peritoneal dialysis, continuous, for ESRD, 176, 179, 183
- Cyclophosphamide, 56
- Cyclosporine
characteristics and properties of, 189
mechanisms of action of, 190
nephrotoxicity of, 34-35; *see also* Chronic cyclosporine nephrotoxicity
- Cyclosporine A (Neoral), 365-366
- Cytokine(s)
CRRT effects on, 313
redox regulation of cytokine gene expression, biliary obstruction, oxidative stress and, 557
see also Cytokine hypothesis; Hyperglycemia, diabetic nephropathy and, biochemical events and cytokines in link between
- Cytokine hypothesis of HD membrane biocompatibility, 204-205
- Cytoskeleton, disruption of, and nephrotoxic ARF, 10-11
- Daily dosing, once-, of aminoglycoside, effects of, on aminoglycoside nephrotoxicity, 29-30
- DCCT (Diabetes Control and Complications Trial) of glycemic control in IDDM nephropathy, 106-109
- Deficiency in AT_{1A} angiotensin II (ANG II) receptor, effects of, 405-410
on ANG II responses, 408-410
on blood pressure regulation, 406-408
on growth and development, 405-406
- Demographics
of ESRD secondary to DM, 331-332
of NIDDM nephropathy, 132-135
see also Age; Sex
- 15-Deoxyspergualin, immunosuppression with, 369
- Depression with ESRD secondary to DM, management of, 340
- Development, *see* Growth and development
- Diabetes Control and Complications Trial (DCCT) of glycemic control in IDDM nephropathy, 106-109
- Diabetes mellitus (DM)
with and without renal insufficiency, as risk factor for CM-AN, 18-19
see also Diabetic nephropathy
- Diabetes mellitus (DM), ESRD secondary to, 331-345
comorbid conditions with, role of AGEs in pathogenesis of, 340-342; *see also* Therapy and management of comorbid conditions in ESRD secondary to DM
demographics and consequences of DM epidemic, 331-332
mortality with, 335
RRT for, 180-182, 333-335
- Diabetic enteropathy in ESRD secondary to DM, management of, 339
- Diabetic nephropathy
introduction to, 77-79
see also Diabetes mellitus, ESRD secondary to; Diabetic nephropathy, ANG II in, RAS and; Glycemic control; Hyperglycemia; Non-insulin-dependent diabetes mellitus nephropathy; Renal hemodynamic basis of diabetic nephropathy; Therapy and management of IDDM nephropathy
- Diabetic nephropathy, ANG II in, RAS and, 441-447
activity of intrarenal RAS in, 442-444
and mechanisms of RAS-induced renal injury, 444
RAS genotypes and, 444-445
and RAS in pathogenesis of diabetic nephropathy, 441-442
systemic RAS in, 442
- Diabetic retinopathy, *see* Retinopathy, diabetic
- Diagnosis-related groups (DRGs), Medicare reimbursement and, 166
- Diagnosis of TB in dialyzed ESRD patients, 356
- Dialysate, HD, in ESRD, 216
- Dialysis
for HRS, 571, 576
see also Adequacy of dialysis; Dose, dialysis; Dialyzer(s); Continuous renal replacement therapy: End-stage renal disease, RRT of; Hemodialysis and entries beginning with terms: Dialysis, Dialyzed
- Dialysis facility
type of, and frequency of dialyzer reuse, 322
see also Future dialysis facility
- Dialysis machines, shared, by ESRD patients, HCV infection transmission through, 348
- Dialysis staff
in future dialysis facility, 303-304
see also Dialysis staff, transmission of infection to
- Dialysis staff, transmission of infection to
of HCV infection by needle-stick injury, 348
patient-to-staff transmission of HIV infection in dialysis unit, 353
- Dialysis ultrafiltrate, HCV infection transmission through, 348-349
- Dialysis unit
HIV transmission in, 352-354
see also Nosocomial infection of HCV infection
- Dialyzed end-stage renal disease (ESRD) patients
TB in, 355-358
see also Dialyzed end-stage renal disease patients, hypertension in; Hemodialysis for ESRD; Hepatitis C virus infection in dialyzed ESRD patients; Human immunodeficiency virus infection in dialyzed ESRD patients; Optimal dialysis dose for ESRD; Peritoneal dialysis for ESRD
- Dialyzed end-stage renal disease (ESRD) patients, hypertension in, 259-264
factors contributing to, 259, 261
management of, 261-263
- Dialyzer(s) (dialyzer membrane), 196-213
biocompatibility of, *see* Biocompatibility of HD membranes
clinical sequelae of choice of, 205-208
composition and structure of, 196-198
future developments in, 209-210
HCV infection transmission through, 348-349
reuse of, *see* Dialyzer reuse for ESRD
transport properties of, 198-202
- Dialyzer (dialyzer membrane) reuse for ESRD, 321-330
complications of, *see* Complication(s) of dialyzer reuse for ESRD
cost reduction with, 165
effects of, 208-209

- epidemiology of, 321-322
 future of, 328-329
 HCV infection transmission through, 349
 history of, 321
 manual versus automated systems of, 323
 types of, 322-323
- Dietary management of diabetic nephropathy
 with dietary protein restriction, 118
 of NIDDM nephropathy, 144
- Direct vasodilators for hypertensive dialyzed ESRD patients, 262, 263
- Disadvantages, *see* Advantages and disadvantages
- Disinfection of dialyzers, 322-327
 disinfectant concentration control problems in, 326-327
 methods of, 322-323
 residual chemical infusion and, 325-326
 and toxicity of disinfectants, 324-325
- Diuretics, 261-263
- PGs and, in cirrhosis, 540
- DM, *see* Diabetes mellitus
- Donor(s), kidney
 need to relax criteria for selection of, to expand donor pool, 378; *see also* Donor pool, expanding
see also Renal transplantation for ESRD
- Donor pool, expanding, 373-380
 with LURDs, 375-376, 378
 strategies to enhance procurement of cadaver kidneys, 376-379
 by using older donors, 373-375
- Dose
 of antitubercular drugs in dialyzed ESRD patients, 357
 effects of once-daily aminoglycoside, on aminoglycoside nephrotoxicity, 29-30
see also Dose, dialysis
- Dose, CAPD, for ESRD, 228-234
 adequacy of, 228-232
 nutrition and, 232-234
see also Optimal dialysis dose for ESRD
- Dose, dialysis
 with CRRT of ARF, 309-310
see also Dose, CAPD, for ESRD
- DRGs (diagnosis-related groups). Medicare reimbursement and, 166
- Drugs, *see* Cancer therapy, renal toxicities of; Nephrotoxicity of immunosuppressive drug(s); Pharmacology and specific drugs; for example: Angiotensin-converting enzyme inhibitors
- Duration
 of ESRD prior to dialysis, as risk factor for HCV infection, 347
 of NIDDM, as risk factor for NIDDM nephropathy, 135
- Efferent event(s) in HRS, 565-571
 adenosine role, 570-571
 decreased ANP levels as, 570
 elevated ET concentrations as, 568-570
 enhanced NO production as, 567-568
 increased sympathetic nervous system activity as, 566-567
 RAS activation as, 565-566
 renal PG alterations as, 566
- Efficiency of HD membrane, 202
- Effluent, disposal of PD, of HIV-infected ESRD patients, 354
- Elderly, the, *see entries beginning with term:* Older
- Endothelins (ETs)
 in biliary obstruction, 558
 in cirrhosis, 511-512
 concentrations of, in HRS, 568-570
 in diabetic nephropathy, 86-87
- Endotoxemia, biliary obstruction, oxidative stress and, 557
- End-stage renal disease (ESRD)
 described, 152
 history of, 153-154
 optimization of management of, 387-390
see also Acute renal failure, CRRT of; Bioartificial kidney; Causes of ESRD; Diabetes mellitus, ESRD secondary to; Dialyzed end-stage renal disease patients; Dialyzer(s); Donor pool, expanding; End-stage renal disease, RRT of; Future dialysis facility; Medicare End-stage Renal Disease Program; Myocardial dysfunction in ESRD; Optimal dialysis dose for ESRD; Predialysis chronic renal failure patients; Rehabilitation of ESRD patient
- End-stage renal disease (ESRD), RRT of, 176-185
 with diabetes mellitus, 180-182, 333-334; *see also* Diabetes mellitus, ESRD secondary to
 in elderly patients, 183-184
 with HIV infection, 182-183, 351; *see also* Human immunodeficiency virus infection in dialyzed ESRD patients
 patient preparation for, 177-180
 patient survival with, *see* Patient survival, ESRD, with RRT
 quality of life with, 177
see also Dialyzed end-stage renal disease patients; Hemodialysis for ESRD; Peritoneal dialysis for ESRD; Renal transplantation for ESRD
- Energetics, alterations in cellular, nephrotoxic ARF and, 4-5
- Enteropathy, diabetic, in ESRD secondary to DM, management of, 339
- Environmental contamination of reused dialyzers, 324
- Environmental renal disease, *see* Occupational and environmental renal disease
- Epidemic, DM, consequences of, 331-332
- Epidemiology
 of dialyzer reuse, 321-322
see also Incidence; Prevalence
- EPO (erythropoietin), *see entries beginning with terms:* Recombinant human erythropoietin
- Equipment, HD, 214-216
- Erythropoietin, *see entries beginning with terms:* Recombinant human erythropoietin
- ESRD, *see* End-stage renal disease
- ET(s), *see* Endothelins
- Etiology of ESRD, *see* Causes of ESRD
- Evidence-based therapy of ESRD
 CQI in, 222-223
 in optimization of ESRD management, 389
- Exemption process, Medicare reimbursement and, 167
- Experimental aminoglycoside nephroprotection, 29
- Experimental cirrhosis, renal effects of ANPs in, 522-525
- External shunts, as vascular access for HD, 239-240
- Extracorporeal blood purification for hepatic failure, 576-582
 with combined filter/sorbent systems and hybrid organ systems, 581

- with CRRT, 578-580
with hemodialysis, 577-578
with hemoperfusion, 580
with TPE, 580-581
- Fibrosis
myocardial calcification and, and myocardial dysfunction in ESRD, 265
see also Fibrosis, as pathway to organ failure; Renal fibrosis
- Fibrosis, as pathway to organ failure, 467-491
tissue repair in, *see* Tissue repair in fibrosis
types of fibrosis, 467-469
- Filter/sorbent systems, combined, blood purification with, in hepatic failure, 581
- Financial incentives to enhance organ donation, 378-379
- Fistula, *see* Arteriovenous fistula in ESRD
- FK506 (tacrolimus; Prograft®)
mechanisms of action of, 190
nephrotoxicity of, 40-41
properties and characteristics of, 189-190, 367-368
- Fluid transport by HD membranes, 198
- Flux of HD membranes, 202
- Frequency of dialyzer reuse, dialysis facility type and, 322
- Future dialysis facility, 298-305
Capitation Payment and, 300-301
impact of managed care on, 298-299
physician supply and, 302-303
quality improvement in, 301-302
reorganization of nephrology and, 299-300
social environment of, 303
staffing and organization of, 303-304
- Gallium nitrate, nephrotoxicity of, 60
- Gastroparesis in ESRD secondary to DM, management of, 339
- Gender, as risk factor for NIDDM nephropathy, 135-136
- Gene(s)
ACE, insertion/deletion polymorphism of, as risk factor for NIDDM nephropathy, 137
expression of cytokine, redox regulation of, biliary obstruction and oxidative stress and, 557
see also Gene targeting
- Gene targeting
RAS, effects of, on renal development, 496-497
see also Angiotensinogen receptor gene targeting; Physiology of type AT₁ angiotensin II receptor, gene targeting approach to
- Genotypes, RAS, in diabetic nephropathy, 444-445
- GFR, *see* Glomerular filtration rate
- Glomerular filtration rate (GFR)
PG effects on, 533
reversible and irreversible causes of decreased, in ESRD, 178
see also Glomerular filtration rate in diabetic nephropathy
- Glomerular filtration rate (GFR) in diabetic nephropathy, 93-98
effects of hemodynamic alterations on, 93-95
hyperfiltration and, 96-98
in IDDM nephropathy, *see* Glomerular filtration rate in IDDM nephropathy, therapeutic interventions and
- in NIDDM nephropathy, 124-126, 130, 137, 138, 142, 143
- Glomerular filtration rate (GFR) in IDDM nephropathy, therapeutic interventions and effects of, 114-117, 120
glycemic control effects on, 101, 104, 109-110
- Glomerular permeability, selective, in NIDDM nephropathy, 126-129
- Glomerulonephritis, immunologically-mediated mercury-induced, 49-50
- Glycation, nonenzymatic, in diabetic nephropathy, 83-85
- Glycation end-products, *see* Advanced glycation end-products
- Glycemic control
and NIDDM nephropathy, 142
see also Glycemic control, relationship between IDDM nephropathy development and
- Glycemic control, relationship between IDDM nephropathy development and, 101-113
controversies over, 109-110
DCCT of, 106-109
natural history of IDDM nephropathy and, 101-102
studies on, 103-106
- Glycemic threshold for IDDM nephropathy, 109
- Goals of ESRD patient, assessing and identifying, in rehabilitation program, 247-248, 250-251
- Government
role of, in CQI of ESRD care, 221-222
see also Medicare End-stage Renal Disease Program
- Graft, *see* Renal graft outcome; Transplantation
- Growth and development
effects of deficiency in AT_{1A} ANG II receptor on, 405-406
tubular, ANG II influence on, 451-452
see also Renin-angiotensin system during renal development
- Growth factor, *see* Transforming growth factor- β ; Transforming growth factor- β_1
- HCFA (Health Care Financing Administration), *see* Medicare End-stage Renal Disease Program
- HCQIP (Health Care Quality Improvement Program) for ESRD care, 220-221
- HCV infection, *see* Hepatitis C virus infection in dialyzed ESRD patients
- HD, *see* Hemodialysis
- Health Care Financing Administration, *see* Medicare End-stage Renal Disease Program
- Health care professionals
organ donation by, strategies to enhance, 376-377
see also Dialysis staff; Physician supply
- Health Care Quality Improvement Program (HCQIP) for ESRD care, 220-221
- Health status and outcome of ESRD patients, optimization of, 389
- Heart fibrosis
described, 469
see also Heart fibrosis, tissue repair in
- Heart fibrosis, tissue repair in, 472-481
ACE and ANG II receptors in, 474-477
ACE inhibition and AT₁ ANG II receptor antagonism in, 478-479
collagen at site of repair in, 473

- elevated circulating ANG II and, 480-481
 inflammatory cell responses in, 469
 myofibroblasts in, 471-472
 TGF- β_1 and, 472-473
- Heart transplantation, chronic cyclosporine nephrotoxicity in, 35-36
- Heat disinfection of dialyzers for reuse, 322-323
- Hemodialysis (HD)
 for blood purification in hepatic failure, 577-578
see also Hemodialysis, vascular access for; Hemodialysis for ESRD
- Hemodialysis (HD), vascular access for, 239-245
 arteriovenous fistula as, *see* Arteriovenous fistula in ESRD
 external shunts as, 239-240
 future, 243-244
 needle-less access as, 242
 permanent catheter access as, 242-243
- Hemodialysis (HD) for ESRD
 CAPD compared with, 234-235; *see also* Continuous ambulatory peritoneal dialysis for ESRD
 equipment used in, 214-216
 HCV infection transmission with, 347
 as RRT option, 176, 177, 179-185
 types of dialysate used in, 216
see also Dialyzer(s); Hemodialysis, vascular access for; Hemodialysis for ESRD secondary to DM; Quality improvement in ESRD care, Medicare Program and
- Hemodialysis (HD) for ESRD secondary to DM, 333
 importance of Kt/V in, 335-336
- Hemodynamics, *see* Renal hemodynamic basis of diabetic nephropathy; Systemic hemodynamics
- Hemofilter, bioartificial, 383-384
- Hemoperfusion, blood purification with, in hepatic failure, 580
- Hepatic failure, *see* Extracorporeal blood purification for hepatic failure
- Hepatitis C virus (HCV) infection in dialyzed ESRD patients, 346-350
 IFN- α therapy of, 350
 prevalence of, 346-347
 risk factors for, 347-348
 transmission of, *see* Nosocomial transmission of HCV infection
- Hepatorenal syndrome (HRS), 563-575
 clinical features of, 563-564
 efferent events in, *see* Efferent event(s) in HRS
 pathogenesis of, 564-565
 PGs in, 541-542
 therapy of, 571-572, 576
- Heterogeneity, axial, of proximal tubule transport by ANG II, 425-426
- High osmolality contrast media (HOCM), LOCM versus, and CM-AN, 19-21
- Histology, renal, in NIDDM nephropathy, proteinuria and, 140-142
- History
 of association between anemia and ESRD, 270
 of dialysis concepts and state of the art prior to 1972, 286-287
 of dialyzer reuse, 321
 of ESRD, 153-154
- of Medicare Program, *see* Legislative and regulatory process in Medicare ESRD Program
 past and present concepts of uremia, 285-286
 of quality improvement in ESRD care, technical and political events in, 218, 219
- of renal transplantation and immunosuppression, 188-189
see also Natural history
- HIV infection, *see* Human immunodeficiency virus infection in dialyzed ESRD patients
- HOCM (high osmolality contrast media), LOCM versus, and CM-AN, 19-21
- Home hemodialysis (HD) for ESRD, 184-185
- Homeostasis disturbances in nephrotoxic ARF, 7-10
 of cell Ca, 7-8
 of phospholipid, 8-10
- Hormonal effects of ANPs, 521
- HPTH, *see* Hyperparathyroidism
- HRS, *see* Hepatorenal syndrome
- Human cirrhosis, *see* Atrial natriuretic peptides in cirrhosis; Circulatory abnormalities in cirrhosis; Prostaglandins in cirrhosis
- Human erythropoietin, *see entries beginning with terms:* Recombinant human erythropoietin
- Human immunodeficiency virus (HIV) infection in dialyzed ESRD patients, 350-352
 choice of RRT for, 182-183, 352
 disposal of PD effluent in, 354
 nosocomial transmission of, 352-354
 patient survival with, 352
 postexposure prophylaxis of HIV infection, 354-355
 prevalence of, 351-352
- Hybrid organ systems, blood purification with, in hepatic failure, 581
- Hydrocarbon nephropathy, light, 51-52
- Hyperfiltration in diabetic nephropathy, 96-98
- Hyperglycemia
 in ESRD secondary to DM, management of, 336-337
 in NIDDM nephropathy, 136-137, 142
see also Glycemic control, relationship between IDDM nephropathy development and; Hyperglycemia, diabetic nephropathy and, biochemical events and cytokines in link between
- Hyperglycemia, diabetic nephropathy and, biochemical events and cytokines in link between, 80-92
 conclusions on, 87-88
 endothelins in, 86-87
 in vitro model of, 80-81
 nonenzymatic glycation in, 83-85
 oxidative stress in, 85-86
 PKC in, 82-83
 polyol pathway in, 81-82
 thromboxane in, 86
- Hyperkalemia, and ACE-related renal failure, 73-74
- Hyperparathyroidism (HPTH)
 myocardial dysfunction and, in ESRD, 264
 secondary, in predialysis CRF patients, pathogenesis of, 275
- Hypertension
 and intrarenal ANG II regulation, 419-420
 low-level lead exposure, renal disease and, 47-48
see also Hypertension in ESRD; Hypertension in IDDM

- nephropathy; Hypertension in NIDDM nephropathy and specific antihypertensive agents
- Hypertension in ESRD
secondary to DM, management of, 336
see also Dialyzed end-stage renal disease patients, hypertension in
- Hypertension in IDDM nephropathy
DCCT effects on, 109
therapy of, 114-118
- Hypertension in NIDDM nephropathy
hypertension as risk factor for NIDDM nephropathy, 136
therapy of, 142-144
- Hypertrophy
left ventricular, and myocardial dysfunction in ESRD, 263-264
tubular, *see* Tubular hypertrophy, ANG II-induced
- IDDM (insulin-dependent diabetes mellitus), *see* Diabetic nephropathy; Glycemic control, relationship between IDDM nephropathy development and; Therapy and management of IDDM nephropathy
- Identification of ESRD patient's goals in rehabilitation program, 247-248
- IFN α (interferon alpha) therapy of HCV infection in dialyzed ESRD patients, 350
- Ifosfamide, nephrotoxicity of, 56-57
- IHD (intermittent hemodialysis) of ESRD, survival with CRRT and, compared, 315
- IL-2 (interleukin-2), 59-60
- Immune function, aging and changes in, renal transplantation in elderly ESRD patients and, 184
- Immunologically-mediated glomerulonephritis, mercury-induced, 49-50
- Immunophilins, *see* Cyclosporine; Cyclosporine A; FK506; Rapamycin
- Immunosuppression, *see* Immunosuppression in renal transplantation for ESRD; Nephrotoxicity of immunosuppressive drug(s) and specific drugs
- Immunosuppression in renal transplantation for ESRD, 188-191, 364-372
with brequinar sodium, 368
history of, 188-189
with immunophilins, *see* Cyclosporine; Cyclosporine A; FK506; Rapamycin
with leflunomide and 15-deoxyspergualin, 369
with monoclonal antibodies, *see* Monoclonal antibody(ies); immunosuppression with
with mycophenolate mofetil, 190-191, 366-367
- Implantable bioartificial kidney, 385-386
- Implementation of rehabilitation program for ESRD patient, 246-251
assessment and identification of patient's goals in, 247-248, 250-251
individualized plan development in, 249-250
- Incidence
of ACE-related renal failure, 68-70
of CM-AN, 17
of ESRD, *see* Incidence of ESRD
see also Prevalence and specific conditions
- Incidence of ESRD
increase in, 172-174
- increase in renal disease and, 174
- Individualized rehabilitation plan for ESRD patient, 248-250
- Induction of tolerance to renal transplantation, 191, 192
- Infection(s)
breakdown in standard infection control practices in dialysis unit, and HCV virus transmission, 348; *see also* Hepatitis C virus infection in dialyzed ESRD patients due to dialyzer reuse, 327
see also Human immunodeficiency virus infection in dialyzed ESRD patients; Tuberculosis
- Inflammatory cell responses, and tissue repair in fibrosis, 469-471
- Information systems, CQI in ESRD care and, 223
- Injury
needle-stick, transmission of HCV infection to dialysis staff by, 348
renal, *see* Renal injury in diabetic nephropathy
- Insertion/deletion polymorphism of ACE gene, as risk factor for NIDDM nephropathy, 137
- Insulin-dependent diabetes mellitus (type I diabetes mellitus), *see* Diabetic nephropathy; Glycemic control, relationship between IDDM nephropathy development and; Therapy and management of IDDM nephropathy
- Integrity of reused dialyzers, 327-328
- Intellectual rehabilitation of ESRD patient, 250
- Intensive care unit, *see* Acute renal failure, CRRT of
- Interferon alpha (IFN α) therapy of HCV infection in dialyzed ESRD patients, 350
- Interleukin-2 (IL-2), 59-60
- Intermittent hemodialysis (IHD) of ESRD, survival with CRRT and, compared, 315
- Intrahepatic porto-systemic shunt, transjugular, for HRS, 572
- Intrarenal angiotensin II (ANG II), 412-422
compartmentalization of, 416-419
levels of, 413-416
in proximal tubule transport, 427-429
regulation of, in normotensive and hypertensive states, 419-420
- Intrarenal renin-angiotensin system (RAS) in diabetic nephropathy, 442-444
- Intratubular renin-angiotensin system (RAS) in ANG II-induced tubular hypertrophy, 449
- In vitro model of hyperglycemia in diabetic nephropathy, 80-81
- In vitro testing of HD membrane transport properties, 198
- Irreversibility of decreased GFR in ESRD, 178
- F₂-Isoprostanes, oxidative stress and formation of, 557-558
- Kidney donors, *see* Donor(s), kidney
- Kidney-pancreas transplantation for ESRD
pancreas transplantation following kidney transplantation versus simultaneous, 188
secondary to DM, 334-335
- Kinetics, urea, as measure of CAPD dose adequacy, 229-232; *see also* Kt/V
- Knockout, gene, *see* Gene targeting
- Kt/V
and optimization of dialysis for ESRD, 291-292
with PD of ESRD secondary to DM, 335-336
- Lead nephropathy, 46-48

- Leflunomide, 369
- Left ventricular hypertrophy (LVH), and myocardial dysfunction in ESRD, 263-264
- Legislative and regulatory process in Medicare ESRD Program
- background of, 153
 - in confrontation era, 163-164
 - in confusion era, 161-162
 - and creation of Medicare, 161-162
 - initial problem with, 162-163
 - national, 154-159
 - pre-Medicare situation and, 160-161
 - reimbursement and, *see Reimbursement, Medicare*
- Leukotrienes (LTs)
- in biliary obstruction, 558
 - biochemical and physiological aspects of, 534
 - in cirrhosis, 542-543
- Light hydrocarbon nephropathy, 51-52
- Lipid management
- in IDDM nephropathy, 119-120
 - of lipid abnormalities in ESRD secondary to DM, 338
- Liver, *see entries beginning with term: Liver and element: Hepat-*
- Liver disease, kidney in
- introduction to, 503-504
 - see also Atrial natriuretic peptides; Bile acids; Circulatory abnormalities in cirrhosis; Extracorporeal blood purification for hepatic failure; Hepatorenal syndrome; Prostaglandins in cirrhosis*
- Liver fibrosis
- described, 469
 - see also Liver fibrosis, tissue repair in*
- Liver fibrosis, tissue repair in
- ACE and ANG II receptors in, 477
 - ACE inhibition and AT₁ ANG II receptor antagonism in, 480
 - collagen at site of repair in, 474
 - inflammatory cell response and, 471
 - myofibroblasts and, 472
- Liver transplantation, orthotopic, for HRS, 571-572
- Living-related donors (LRDs), 374, 375
- Living-unrelated donors (LURDs), 191-192
- expanding donor pool by using, 375-376, 378
- Local action of ANG II, systemic versus, 401-403
- LOCM (low osmolality contrast media), HOCM versus, and CM-AN, 19-21
- Loss of vascular access in HD, 241
- Low-level lead exposure, renal disease, hypertension and, 47-48
- Low osmolality contrast media (LOCM), HOCM versus, and CM-AN, 19-21
- LRDs (living-related donors), 374, 375
- LTs, *see Leukotrienes*
- Lung fibrosis
- described, 469
 - see also Lung fibrosis, tissue repair in*
- Lung fibrosis, tissue repair in, 470-474
- ACE and ANG II receptors in, 477
 - ACE inhibition and AT₁ ANG II receptor antagonism in, 480
 - collagen at site of repair in, 474
- inflammatory cell response and, 470-471
- myofibroblasts in, 472
- TGF- β_1 in, 473
- LURDs, *see Living-unrelated donors*
- LVH (left ventricular hypertrophy), and myocardial dysfunction in ESRD, 263-264
- β (beta)₂M (microglobulin) amyloidosis, HD membranes and, 206
- Malnutrition in ESRD secondary to DM, management of, 337-338
- Managed care, impact of, on future dialysis facility on, 298-299
- Manual systems of dialyzer reuse, automated versus, 323
- Materials and composition
- of AVF, 241-242
 - of HD membranes, 196-198
- Medicare End-stage Renal Disease (ESRD) Program
- future of, 159
 - and history of ESRD, 153-154
 - introduction to, 149-151, 253-256
 - see also End-stage renal disease; Legislative and regulatory process in Medicare ESRD Program; Quality improvement in ESRD care; Medicare Program and Membranes, HD, *see Dialyzer(s)**
- Mercury, 49-50
- Mesangial cells, PG effects on function of, 533
- Metabolic acidosis in ESRD
- myocardial dysfunction and, 265
 - in predialysis patients, 277-280
- Metabolism
- of mercury, renal disease and, 49
 - PGI₂, in cirrhosis, 543-544
- Method II of Medicare reimbursement, 166
- Methotrexate, 58-59
- Microalbuminuria in IDDM nephropathy, DCCT effects on, 106-109
- β_2 Microglobulin (β_2 m) amyloidosis, HD membranes and, 206
- Middle molecules
- enhancing HD membrane removal of, 209
 - HD membrane transport of, 199-200
- Minorities, strategies to enhance organ donations by, 377-378
- Mitomycin C, 58
- Mitramycin (plicamycin), 58
- MMF (mycophenolate mofetil), 190-191, 366-367
- Monoclonal antibody(ies), immunosuppression with, 369-370
- with OKT3, 191, 369
- Monthly Capitation payment in Medicare Program, 167
- and future dialysis facility, 300-301
- Morphology, renal, in NIDDM nephropathy, 128-130
- Mortality, ESRD
- due to reused dialyzer, 328
 - secondary to DM, 335
 - in U.S., 289-290
- Motor neuropathy in ESRD secondary to DM, management of, 339
- Multiple myeloma, as risk factor for CM-AN, 19
- Mycobacterium chelonei* infections, reused dialyzer and, 327

- Mycophenolate mofetil (S 61143; MMF), 190-191, 366-367
- Myocardial dysfunction in ESRD, 257-269
anemia and, 257-260, 264
hyperparathyroidism and, 264
hypertension and, *see* Dialyzed end-stage renal disease patients, hypertension in
LVH and, 263-264
management of, 265-266
metabolic acidosis, autonomic dysfunction and, 265
myocardial fibrosis and calcification and, 265
- Myocardial fibrosis and calcification, and myocardial dysfunction in ESRD, 265
- Myofibroblasts in tissue repair in fibrosis, 471-472
- Na transport, *see* Sodium transport, PG effects on
- National Cooperative Dialysis Study (NCDS), 287-289
- National Health Institutes (NIH), and optimization of dialysis, 290-291
- National legislation for Medicare ESRD Program, 154-159
- Natriuretic peptide, *see* Atrial natriuretic peptides
- Natural history
of IDDM nephropathy, 101-102
of NIDDM nephropathy, 137-139
- NCDS (National Cooperative Dialysis Study), 287-289
- Needle-less vascular access for HD, 242
- Needle-stick injury, transmission of HCV infection to dialysis staff by, 348
- Neoral (cyclosporine A), 365-366
- Nephrologists, supply of, in future dialysis facility, 302-303
- Nephrology, reorganization of, and future dialysis facility, 299-300
- Nephroprotection, experimental aminoglycoside, 29
- Nephrotoxicity, *see* Nephrotoxicity of immunosuppressive drug(s); Toxic nephropathies
- Nephrotoxicity of immunosuppressive drug(s), 34-45
of cyclosporine, 34-35; *see also* Chronic cyclosporine nephrotoxicity
of FK506, 40-41
of rapamycin, 41
- Nephrotoxin
determinants of uptake of, in nephrotoxic ARF and, 3-4
see also Toxic nephropathies
- Nervous system, sympathetic, activity of, in HRS, 566-567
- Neurohumoral regulation in cirrhosis, relationship between systemic hemodynamics and, 512-513
- Neuropathy, autonomic, motor, and sensory, in ESRD secondary to DM, management of, 339
- Neutrophils, activation of, as index of HD membrane biocompatibility, 203-204
- NIDDM (non-insulin-dependent diabetes mellitus), *see* Non-insulin-dependent diabetes mellitus nephropathy
- NIH (National Health Institutes), and optimization of dialysis, 290-291
- Nitric oxide (NO)
in cirrhosis, 510-511
production of, in HRS, 567-568
- Nitrosoureas, 57-58
- NO, *see* Nitric oxide
- Nonenzymatic glycation in diabetic nephropathy, 83-85
- Nonheart-beating donor programs to expand donor pool, 378
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus) nephropathy, 124-147
demographics of, 132-135
GFR in, 125-126
natural history of, 137-139
prevention of, and intervention in, 142-144
with proteinuria, renal histology in, 140-142
renal morphology in, 128-130
retinopathy and, 139-140
risk factors for, 135-137
selective glomerular permeability in, 126-129
study background, 124-125
see also Diabetic nephropathy
- Non-steroidal anti-inflammatory drugs, *see* Prostaglandins in cirrhosis
- Normotensive states, intrarenal ANG II regulation in, 419-420
- Nosocomial transmission
of HIV infection, 352-354
of TB, 358
see also Nosocomial transmission of HCV infection
- Nosocomial transmission of HCV infection, 348-350
modes of, 348-349
prevalence of HCV infection as risk factor for, 347
strategies to control, 349-350
- NSAIDs (non-steroidal anti-inflammatory drugs), *see* Prostaglandins in cirrhosis
- Nutrition
and CAPD dose for ESRD, 232-234
see also Dietary management of diabetic nephropathy
- Observational studies on glycemic control in IDDM nephropathy, 103-104
- Obstruction, biliary, *see* Biliary obstruction, effects of
- Occupational and environmental renal disease, 46-53
beryllium-, arsenic-, and chromium-induced, 51
cadmium nephropathy as, 48-49
due to solvents, 51-52
lead nephropathy as, 46-48
mercury nephrotoxicity as, 49-50
silicon-induced, 50-51
uranium-induced, 50
- OKT3, 191, 369
- Older donors, expanding donor pool by using, 373-375
- Older ESRD patients, RRT of, 183-184
- OLT (orthotopic liver transplantation) for HRS, 571-572
- Once-daily dosing of aminoglycoside, effects of, on nephrotoxicity, 29-30
- Oncocytically active proteins, transport of, by HD membranes, 200
- OPO (Organ Procurement Office), routine referral of potential donors to, 378
- Optimal dialysis dose for ESRD, 285-297
current controversies on, 293-294
dialysis concepts and state of the art prior to 1972, 286-287
mortality rates in U.S. and, 289-290
- NCDS and, 287-289
- NIH and, 290-291
past and present concepts of uremia and, 285-286
pitfalls of quantification of, 292-293

- urea clearance measurement, Kt/V and, 291-292
- Organ failure, *see* Acute renal failure; Angiotensin-converting enzyme inhibitors, renal failure related to; End-stage renal disease; Fibrosis, as pathway to organ failure
- Organ Procurement Office (OPO), routine referral of potential donors to, 378
- Organization of future dialysis facility, 303-304
- Orthotopic liver transplantation (OLT) for HRS, 571-572
- Osteodystrophy, *see* Renal osteodystrophy
- Outcome, *see* Outcome of ARF; Outcome of ESRD; Renal graft outcome and specific conditions
- Outcome of ARF
- with CRRT, 315-316
 - HD membrane effects on, 207
- Outcome of ESRD
- HD membranes and, 207-208
 - RRT and, 176-177
 - see also* Mortality, ESRD; Patient survival, ESRD
- Oxidative stress
- defined, 554
 - in diabetic nephropathy, 85-86
 - and nephrotoxic ARF, 5-7
 - see also* Oxidative stress, bile acids and
- Oxidative stress, bile acids and, 554-558
- association between, 555-556
 - biliary obstruction and, 557-558; *see also* Biliary obstruction, effects of cholestasis and, 556
- PAI-1 (plasminogen activator inhibitor-1), link between ANG II and, in renal fibrosis, 459-460
- Pancreas transplantation, *see* Kidney-pancreas transplantation for ESRD
- Pathogenesis and pathophysiology
- of ACE-related renal failure, 70-71
 - of chronic cyclosporine nephrotoxicity, 38-40
 - of CM-AN, 15-16
 - of comorbid conditions with ESRD secondary to DM and, role of AGEs in, 340-342
 - of diabetic nephropathy, RAS in, 441-442
 - of HRS, 564-565
 - of nephrotoxic ARF, *see* Acute renal failure, nephrotoxic or secondary HPTH in predialysis CRF patients, 275
- Patient goals, assessment and identification of ESRD, in rehabilitation program, 247-248, 250-251
- Patient-to-patient transmission of HIV infection in dialysis unit, 352-353
- Patient preparation for RRT of ESRD, 177-180
- Patient selection for RRT of ESRD, 178-179
- Patient-to-staff transmission of HIV infection in dialysis unit, 353
- Patient survival, ESRD
- HIV-infected, 352
 - see also* Patient survival, ESRD, with RRT
- Patient survival, ESRD, with RRT, 176-177
- with CRRT and IHD, compared, 315
- Payment for ESRD care, *see* Reimbursement, Medicare
- PCRn (protein catabolic rate), importance of, in NCDS, 288-289
- Peptide
- calcitonin-gene related, in cirrhosis, 510
- see also* Atrial natriuretic peptides
- Peripheral vascular disease in ESRD secondary to DM, management of, 338-339
- Peritoneal dialysis (PD) for ESRD, 181-183
- access for, 180
 - continuous ambulatory, *see* Continuous ambulatory peritoneal dialysis for ESRD
 - continuous cycling, 176, 179, 183
 - with HCV infection, 347
 - with HIV infection, disposal of PD effluent as postexposure prophylaxis, 354
- Peritoneal dialysis (PD) for ESRD secondary to DM, 333-336
- importance of Kt/V in, 335-336
- Permanent vascular access for HD with catheters, 242-243
- Permeability
- of HD membranes, 202
 - selective glomerular, in NIDDM nephropathy, 126-129
- PG(s), *see* Prostaglandins
- PGI₂ (prostacyclin), systemic production and metabolism of, in cirrhosis, 543-544
- Pharmacology
- of aminoglycosides, 27-28
 - pharmacological blockade of RAS during renal development, 495-496
 - pharmacological effects of ANP infusion in cirrhosis, 521
 - pharmacological evidence for role of RAAS in progression of renal disease, 431-432
 - see also* specific drugs
- Phenotypes, 396-401
- ANG II receptor, 397-401
 - angiotensinogen, 396-397
- Phospholipid homeostasis, disturbances of, in nephrotoxic ARF, 8-10
- Physical proximity to HCV-infected dialysis patients, as risk factor for transmission, 348
- Physical rehabilitation of ESRD patient, 248-249
- Physician supply in future dialysis facility, 302, 303
- Physiology
- of PGs and, 530-534
 - renal, bile acid effects on, 551-552
 - see also* Physiology of AT_{1A} angiotensin II receptor, gene targeting approach to
- Physiology of AT_{1A} angiotensin II (ANG II) receptor, gene targeting approach to, 404-411
- and deficiency in AT_{1A} receptor, *see* Deficiency in AT_{1A} angiotensin II receptor, effects of
 - functions and role of ANG II receptors, 404-405
- PKC (protein kinase C) in diabetic nephropathy, 82-83
- Plasma atrial natriuretic peptides (ANPs), renal effects of, 521-522
- Plasma bile acids in liver disease, 550-551
- Plasma exchange, therapeutic, in hepatic failure, blood purification with, 580-581
- Plasminogen activator inhibitor-1 (PAI-1), link between ANG II and, in renal fibrosis, 459-460
- Plicamycin, 58
- Political events in history of ESRD care quality improvement, 218, 219
- Polymorphism, insertion/deletion, of ACE gene, as risk factor for NIDDM nephropathy, 137

- Polyol pathway, and hyperglycemia in diabetic nephropathy, 81-82
- Porto-systemic shunt, transjugular intrahepatic, for HRS, 572
- Postexposure prophylaxis of HIV infection, 354-355
- Potentially unattributed causes of ESRD, 171-172
- Predialysis chronic renal failure (CRF) patients, 270-284
anemia in, *see* Anemia in predialysis CRF patients
metabolic acidosis in, 277-280
renal bone disease in, 274-277
- Pre-Medicare era
CAPD for ESRD in, 227
ESRD regulations and legislation in, 160-161
- Presumed consent for organ donation, need for legislation on, 378
- Prevalence
of dialyzer reuse, 321-322
see also Prevalence of infection(s) in dialyzed ESRD patients
- Prevalence of infection(s) in dialyzed ESRD patients
HCV, 346-347
HIV, 351-352
TB, 355
- Prevention
of ACE-related renal failure, 74-75
of CM-AN, 21-22
of ESRD, optimization of, 388-389
with experimental aminoglycoside nephroprotection, 29
of NIDDM nephropathy, 142-144
see also Prophylaxis
- Prograft®, *see* FK506
- Progression of renal disease
rHuEPO effects on, in predialysis CRF patients, 273
see also Renin-angiotensin-aldosterone system, role of, in renal disease progression
- Progressive renal insufficiency in IDDM nephropathy, anti-hypertensive therapy effects on, 115
- Prophylaxis
postexposure, of HIV infection, 354-355
of TB infection, 357-358
see also Prevention
- Prostacyclin (PGI₂), systemic production and metabolism of, in cirrhosis, 543-544
- Prostaglandins (PGs)
biochemical and physiological aspects of, 530-534
in HRS, 541-542
renal, 566
see also Prostaglandins in cirrhosis
- Prostaglandins (PGs) in cirrhosis, 530-548
administration of, 544-545
altered systemic production and metabolism of PGI₂, 543-544
biochemical and physiological aspects of PGs and, 530-534
diuretics and, 540
and hepatorenal syndrome, 541-542
Na handling and, *see* Sodium transport. PG effects on renal function and, 536-539
water transport and, *see* Water transport. PG effects on
- Protein(s)
adsorption of, by HD membranes, 200-202
alterations in synthesis of, in nephrotoxic ARF, 11
- metabolism of, effects of metabolic acidosis in predialysis
CRF patients on, 278-279
- oncotic active, HD membrane transport of, 200
- restriction of dietary, in IDDM nephropathy management, 118
see also Protein catabolic rate; Proteinuria
- Protein catabolic rate (PCRn), importance of, in NCDS, 288-289
- Protein kinase C (PKC) in diabetic nephropathy, 82-83
- Proteinuria
NIDDM nephropathy with, histology and, 140-142
see also Albumin excretion
- Proximal tubule
cadmium nephropathy and dysfunction of, 48-49
see also Proximal tubule transport, ANG II regulation of
- Proximal tubule transport, ANG II regulation of, 423-430
ANG II receptors and, 425-426
axial heterogeneity of ANG II regulation, 426
intrarenal ANG II, 427-429
systemic ANG II, 423-425
tubuloglomerular feedback mechanism and, 426-427
- PRs (pyrogen reactions) to reused dialyzers, 326-327
- Psychological rehabilitation of ESRD patient, 249-250
- Public education on organ donation, need for, 376-377
- Pyrogen reactions (PRs) to reused dialyzers, 326-327
- Quality assurance (QA) in ESRD care, 219-220
- Quality improvement (QI) in ESRD care
in future dialysis facility, 301-302
see also Quality improvement in ESRD care, Medicare Program and
- Quality improvement (QI) in ESRD care, Medicare Program and, 218-225
continuous, *see* Continuous quality improvement in ESRD care
future of, 223-224
HCQIP and, 220-221
quality assurance and, 219-220
reimbursement and, 218-219
- Quality of life (QOL) with RRT of ESRD, 177
- Quantification of optimal dialysis does for ESRD, pitfalls of, 292-293
- RAAS, *see* Renin-angiotensin-aldosterone system, role of, in renal disease progression
- Rapamycin (sirolimus), 41, 190, 368-369
- RAS, *see* Renin-angiotensin system
- Rationalization, optimization and, of ESRD management, 389-390
- RBF (renal blood flow), PG effects on, 533
- Reactive fibrosis, described, 468
- Recombinant human erythropoietin (rHuEPO) for anemia of ESRD
cardiovascular effects of, 258-259, 261
Medicare reimbursement for, 166-167
see also Recombinant human erythropoietin for predialysis anemia in CRF
- Recombinant human erythropoietin (rHuEPO) for predialysis anemia in CRF, 271-274
benefits of, 273-274
concerns about, 271-272

- safety of, 272-273
- Redox regulation of cytokine gene expression, biliary obstruction, oxidative stress and, 557
- Reduction of Medicare payments, regulations and, 164-166
- Referral of ESRD patient for renal transplantation, contraindications to, 180
- routine potential donor, to Organ procurement Office, 378
- Regenerated cellulose hemodialysis (HD) membranes, 196-197
- Regulatory process in Medicare ESRD Program, *see* Legislative and regulatory process in Medicare ESRD Program
- Rehabilitation of ESRD patient, 246-252
- cost-effectiveness of, 251
 - defined, 246
 - implementing program of, *see* Implementation of rehabilitation program for ESRD patient
- Reimbursement, Medicare
- DRGs, Method II and, 166
 - for EPO therapy, 166-167
 - exemption process and, 167
 - Monthly Capitation payment, *see* Monthly Capitation payment in Medicare Program
 - quality improvement and, 218-219
 - regulations to hold or reduce, 164-166
 - for renal transplantation, 167-168
 - secondary payor provision in, 166
- Renal abnormalities, disturbed RAS during renal development and, 497-499
- Renal blood flow (RBF), PG effects on, 533
- Renal development, *see* Renin-angiotensin system during renal development
- Renal disease
- increase in, and increase in ESRD, 174; *see also* End-stage renal disease
 - see also specific renal diseases*
- Renal failure, *see* Acute renal failure; Angiotensin-converting enzyme inhibitors, renal failure related to; End-stage renal disease; Hepatorenal syndrome and specific nephropathies
- Renal fibrosis
- described, 469
 - see also* Renal fibrosis, ANG II in; Renal fibrosis, tissue repair in
- Renal fibrosis, ANG II in, 455-466
- ANG II-PAI-1 link in, 459-460
 - role of ANG II in, 457-459
 - TGF- β and, *see* Transforming growth factor- β in renal fibrosis
- Renal fibrosis, tissue repair in, 472-474
- ACE and ANG II receptors in, 477
 - ACE inhibition and AT₁ ANG II receptor antagonism in, 479-480
 - collagen at site of repair in, 473-474
 - inflammatory cell response and, 469-470
 - myofibroblasts in, 472
 - TGF- β_1 and, 472-473
- Renal function
- bile acid effects on, 551-554
 - in cirrhosis, 536-541
 - see also* Liver disease, kidney in *specific conditions and aspects of renal function*
- Renal graft outcome
- factors influencing, 191
 - see also* Renal graft survival
- Renal graft survival
- according to donor age, 374
 - according to donor-recipient relationship, 376
- Renal handling of aminoglycosides, 27-28
- Renal hemodynamics basis of diabetic nephropathy, 93-100
- hemodynamic alterations, 93-95
 - hypoperfusion and, 96-98
 - mechanisms of renal injury and, 95-96
- Renal histology in NIDDM nephropathy, proteinuria and, 140-142
- Renal injury in diabetic nephropathy
- mechanisms of, 95-96
 - RAS-induced, mechanisms of, 444
- Renal insufficiency
- progressive, blood pressure control effects on, 115
 - as risk factor for CM-AN, 17-19
- Renal membrane function, biliary obstruction effects on, 553-554
- Renal morphology in NIDDM nephropathy, 128-130
- Renal osteodystrophy (bone disease)
- in ESRD secondary to DM, management of, 339-340
 - in predialysis CRF patients, 274-277
- Renal-pancreas transplantation, *see* Kidney-pancreas transplantation for ESRD
- Renal Physicians Association (RPA), CQI in ESRD care and, 222
- Renal physiology, bile acid effects on, 551-552
- Renal prostaglandins (PGs)
- in HRS, 566
 - see also* Prostaglandins in cirrhosis
- Renal replacement therapy, *see* Continuous renal replacement therapy; Dialysis; End-stage renal disease, RRT of; Kidney-pancreas transplantation for ESRD; Renal transplantation for ESRD
- Renal transplantation, *see* Kidney-pancreas transplantation for ESRD; Renal transplantation for ESRD
- Renal transplantation for ESRD, 188-193
- antilymphocyte agents and tolerance induction in, 191, 192
 - diabetic ESRD, 181, 182
 - in elderly patients, 184
 - graft outcome in, 191
 - history of, 188-189
 - with HIV infection, 182
 - immunosuppression in, *see* Immunosuppression in renal transplantation for ESRD
 - with LURDs, 191-192
 - Medicare reimbursement for, 167-168
 - referral for, 180
 - secondary to DM, 334
 - xenotransplantation, 192-193, 379
 - see also* Kidney-pancreas transplantation for ESRD
- Renal tubules, *see* Tubules
- Renin
- PG effects on release of, 533
 - see also entries beginning with terms:* Renin-angiotensin Renin-angiotensin-aldosterone system (RAAS), role of, in renal disease progression, 431-440
 - aldosterone links to disease progression, 435-437

- pharmacological evidence for, 431-432
renin-angiotensin axis in, 432-435
- Renin-angiotensin system (RAS)
activation of, in HRS, 565-566
intratubular, in ANG II-induced tubular hypertrophy, 449
role of, in progression of renal disease, 432-435
see also Renin-angiotensin system during renal development
- Renin-angiotensin system (RAS) during renal development, 492-501
effects of RAS gene targeting on, 496-497
expression of, 492-495
mechanisms of renal abnormalities and disturbed, 497-499
pharmacological blockade of, 495-496
- Reorganization of nephrology, future dialysis facility and, 299-300
- Reparative (replacement) fibrosis, described, 467-468
- Reprocessed dialyzers, *see* Dialyzer reuse
- Residual chemical infusion with reused dialyzers, 325-326
- Resistance to ANPs in cirrhosis, renal effects of, 527
- Retinopathy, diabetic
in ESRD secondary to DM, management of, 340
and NIDDM nephropathy, 139-140
- Reuse of dialyzers, *see* Dialyzer reuse
- Reversibility
of ACE-related renal failure, 71-72
of decreased GFR in ESRD, 178
- rHuEPO, *see entries beginning with terms:* Recombinant human erythropoietin
- Risk factors
for CM-AN, 17-18
for HCV infection in dialyzed ESRD patients, 347-348
for NIDDM nephropathy, 135-137
- Routine referral of potential donors to Organ procurement Office, 378
- RPA (Renal Physicians Association), CQI in ESRD care and, 222
- RRT (renal replacement therapy), *see* Continuous renal replacement therapy; Dialysis; End-stage renal disease, RRT of; Kidney-pancreas transplantation for ESRD; Renal transplantation for ESRD
- S 61143 (mycophenolate mofetil), 190-191, 366-367
- Safety of rHuEPO for predialysis anemia in CRF, 272-273
- Secondary hyperparathyroidism (HPTH) in predialysis CRF patients, pathogenesis of, 275
- Secondary payor provision in Medicare Program, 166
- Selective glomerular permeability in NIDDM nephropathy, 126-129
- Sensory neuropathy in ESRD secondary to DM, management of, 339
- Sex, as risk factor for NIDDM nephropathy, 135-136
- Shared dialysis machines by ESRD patients, HCV infection transmission through, 348
- Shunts
external, as vascular access for HD of ESRD, 239-240
transjugular intrahepatic porto-systemic, for HRS, 572
- Sieving coefficient of HD membranes, 200
- Silicon-induced nephropathy, 50-51
- Sirolimus (rapamycin), 41, 190, 368-369
- Small solutes, enhancing removal of, with HD membranes, 209
- Smooth muscle, PG effects on function of, 533
- Social environment of future dialysis facility, 303
- Social rehabilitation of ESRD patient, 249
- Sodium (Na) transport, PG effects on, 533
in cirrhosis, 539-540
- Solutes, enhancing removal of small, with HD membranes, 209
- Solvents, nephrotoxicity of, 51-52
- Staff, *see* Dialysis staff
- Stage 1 of NIDDM development, 137-138, 140
- Stage 2 of NIDDM development, 138, 140
- Stage 3 of NIDDM development, 138, 140
- Stage 4 of NIDDM development, 138-139, 140
- Stage 5 of NIDDM development, 139, 140
- Standard infection control practices in dialysis unit, breakdown in, and HCV virus transmission, 348
- Stress, *see* Oxidative stress
- Structure of HD membranes, 196-198
- Supply of nephrologists in future dialysis facility, 302-303
- Survival, *see* Patient survival, ESRD; Renal graft survival
- Sympathetic nervous system, activity of, in HRS, 566-567
- Synthetic hemodialysis (HD) membranes, 197-198
- Systemic action of ANG II, local versus, 401-403
- Systemic angiotensin II (ANG II), proximal tubule transport regulation and, 423-425
- Systemic hemodynamics
biliary obstruction effects on, 554
in cirrhosis, *see* Systemic hemodynamics in cirrhosis
effects of ANPs on, 521
- Systemic hemodynamics in cirrhosis
abnormalities of, 506-508
relationship between neurohumoral regulation and, 512-513
- Systemic prostacyclin (PGI₂), production and metabolism of, in cirrhosis, 543-544
- Systemic renin-angiotensin system (RAS) in diabetic nephropathy, 442
- Tacrolimus, *see* FK506
- TB (tuberculosis) in dialyzed ESRD patients, 355-358
- Technical events in history of ESRD care quality improvement, 218, 219
- TGF, *see* Transforming growth factor- β ; Transforming growth factor- β_1
- Therapeutic plasma exchange (TPE) in hepatic failure, blood purification with, 580-581
- Therapy and management
of ACE-related renal failure, 74-75
ANG II blockade, effects of, on TGF- β in renal fibrosis, 460-462
antihypertensive, *see specific antihypertensive agents*
dietary, *see* Dietary management of diabetic nephropathy; Nutrition
- of ESRD, *see* Therapy and management of ESRD
of HRS, 571-572, 576
- immunosuppressive, *see* Immunosuppression in renal transplantation for ESRD; Nephrotoxicity of immunosuppressive drug(s)
- of lead nephropathy, 48

- nephrotoxicity due to. *see* Acute renal failure, nephrotoxic; Aminoglycoside nephrotoxicity; Angiotensin-converting enzyme inhibitors, renal failure related to; Cancer therapy, renal toxicities of; Contrast media-associated nephropathy; Nephrotoxicity of immunosuppressive drug(s); Occupational and environmental renal disease of NIDDM nephropathy, 142-144
- PG, of cirrhosis, 544-545
- renal replacement, *see* Continuous renal replacement therapy; Dialysis; End-stage renal disease, RRT of; Kidney-pancreas transplantation for ESRD; Renal transplantation for ESRD
- see also* Glycemic control; Therapy and management of IDDM nephropathy specific drugs and specific conditions
- Therapy and management of comorbid conditions in dialyzed ESRD patients
- of HCV infection with IFN α , 350
 - of hypertension, 261-263
 - of myocardial dysfunction, 265-266
 - of TB, 356-357
- Therapy and management of comorbid conditions in ESRD
- secondary to DM, 336-340
 - of AGE accumulation, 342
 - of coronary artery disease and peripheral vascular disease, 338-339
 - dialysis adequacy and, 336
 - of gastroparesis and diabetic enteropathy, 339
 - of hyperglycemia, 336-337
 - of hypertension, 336
 - of lipid abnormalities, 338
 - of malnutrition, 337-338
 - of motor, sensory, and autonomic neuropathy, 339
 - of renal osteodystrophy, 339-340
 - of retinopathy and depression, 340
- Therapy and management of comorbid conditions in predialysis CRF patients
- alkali therapy of metabolic acidosis, 280
 - EPO for anemia, *see* Recombinant human erythropoietin for predialysis anemia in CRF
 - vitamin D $_3$ metabolite, of renal bone disease, 275-277
- Therapy and management of ESRD
- optimization of, 387-390
 - renal replacement, *see* End-stage renal disease, RRT of
 - see also* Therapy and management of comorbid conditions in dialyzed ESRD patients; Therapy and management of comorbid conditions in ESRD secondary to DM; Therapy and management of comorbid conditions in predialysis CRF patients
- Therapy and management of IDDM nephropathy, 114-123
- with aldose reductase inhibitors, 118-119
 - with anti-lipidemic agents, 119-120
 - with blood pressure control, 114-118
 - with dietary protein restriction, 118
 - other agents in, 120
 - see also* Glycemic control, relationship between IDDM nephropathy development and
- Thromboxane(s) (TX)
- biochemical and physiological aspects of, 530-534
 - in diabetic nephropathy, 86
 - in HRS, 541-542
- Thromboxane A $_2$ (TXA $_2$), and renal function in cirrhosis, 540-541
- TIPS (transjugular intrahepatic porto-systemic shunt) for HRS, 572
- Tissue repair in fibrosis
- ACE and ANG II receptors in, 474-478
 - ACE inhibition and AT $_1$ receptor antagonism and, 478-479
 - collagen at site of, 473-474
 - elevated circulating ANG II and, 480-481
 - inflammatory cell responses in, 469-471
 - myofibroblasts in, 471-472
 - other modulators of, 481-482
 - paradigm of, 482-483
 - TGF- β_1 and, 472-473
- Tolerance to renal transplantation, induction of, 191, 192
- Toxic nephropathies
- introduction to, 1-2
 - see also* Acute renal failure, nephrotoxic; Aminoglycoside nephrotoxicity; Angiotensin-converting enzyme inhibitors, renal failure related to; Cancer therapy, renal toxicities of; Contrast media-associated nephropathy; Nephrotoxicity of immunosuppressive drug(s); Occupational and environmental renal disease
- Toxicity
- chemical, of reused dialyzers, 324-325
 - see also* Nephrotoxicity of immunosuppressive drug(s); Toxic nephropathies
- TPE (therapeutic plasma exchange) in hepatic failure, blood purification with, 580-581
- Transforming growth factor- β (TGF- β)
- and diabetic nephropathy, 86-87
 - see also* Transforming growth factor- β in renal fibrosis
- Transforming growth factor- β (TGF- β) in renal fibrosis
- ANG II blockade effects on, 460-462
 - role of, 455-457
 - stimuli for elevated, 457
- Transforming growth factor- β_1 (TGF- β_1), and tissue repair in fibrosis, 472-473
- Transfusions, number of received blood, as risk factor for HCV infection, 347
- Transjugular intrahepatic porto-systemic shunt (TIPS) for HRS, 572
- Transmission of infections, *see* Nosocomial transmission
- Transplantation
- bone marrow, nephrotoxicity of, 60-62
 - chronic cyclosporine nephrotoxicity in, 35-37
 - orthotopic liver, for HRS, 571-572
 - pancreas, *see* Kidney-pancreas transplantation for ESRD
 - see also* Renal transplantation for ESRD
- Transport properties of HD membranes, 198-202
- Tuberculosis (TB) in dialyzed ESRD patients, 355-358
- Tubular growth, ANG II influence on, 451-452; *see also* Tubular hypertrophy, ANG II-induced
- Tubular hypertrophy, ANG II-induced, 448-454
- and ANG II influence on tubular growth, 451-452
 - and importance of tubular hypertrophy, 448-449
 - intratubular RAS and, 449
 - mechanisms of, 449-451
- Tubules
- bioartificial, 384-385

- see also* Proximal tubule and entries beginning with term: Tubular and element: Tubulo-Tubuloglomerular feedback mechanism, proximal tubule transport regulation by ANG II and, 426-427 TXs, *see* Thromboxane(s); Thromboxane A₂ Type I diabetes mellitus (insulin-dependent diabetes mellitus), *see* Diabetic nephropathy; Glycemic control, relationship between IDDM nephropathy development and; Therapy and management of IDDM nephropathy Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Ultrafiltrate, dialysis, HCV infection transmission through, 348-349 Ultrafiltration coefficient of HD membranes, 198 Unattributed causes of ESRD, 171-172 Unrelated donors, *see* Living-unrelated donors Uranium-induced nephropathy, 50 Urea kinetics of, as measure of CAPD dose adequacy, 229-232; *see also* Kt/V transport of, by HD membranes, 198-199 Uremia, *see* End-stage renal disease Uremic acidosis in ESRD, *see* Metabolic acidosis in ESRD Urinary bile acids in liver disease, 550-551 Urinary excretion, albumin, *see* Albumin excretion Vascular access for RRT of ESRD, 179-180 problems of, in ESRD secondary to DM, 339 *see also* Hemodialysis, vascular access for Vascular disease, peripheral, in ESRD secondary to DM, amputation and, 339 Vasoactive substances, abnormalities of, in cirrhosis, 509-512 in ANPs and CGRP, 510; *see also* Atrial natriuretic peptides in cirrhosis in ETs, 511-512 in NO and catecholamines, 510-511 Vasodilators, direct, for hypertensive dialyzed ESRD patients, 262, 263 Ventricular hypertrophy, left, and myocardial dysfunction in ESRD, 263-264 Vitamin D₃ metabolites for renal bone disease in predialysis CRF patients, 275-277 Volume overload, chronic, and myocardial dysfunction in ESRD, 264 Water immersion in study of renal effects of ANPs in cirrhosis, 525-527 Water transport, PG effects on, 534 in cirrhosis, 539-540 Xenotransplantation, 192-193, 379